MARK2 and breast carcinoma: This work confirmed that a type I TGF-β receptor serine/threonine kinase inhibitor could synergistically enhance the CD8+ T cell host immune response to Her2/neu and effectively suppress the progression of a Her2/neu-expressing 4T1 breast cancer model (55).